WaveMan
WaveMan · Company
ARDX · Ardelyx, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ARDX Ardelyx (ARDX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001437402
Quote by TradingView
Form 144 · 8
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
132
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $92.6K priced

What the filings say about ARDX

Insiders, 180 days
-$2.2M net sold
8 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$523.7K
8 notices

Ardelyx insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ARDELYX, INC. insiders sold a net $2.2M of stock across 346 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
RAAB MICHAEL
President & CEO
SELL
2026-08-25 SECtraded 2026-08-21
15,009
$57.9K
-21.7%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (1 buy, 61 sales), the last on Jul 15, 2026.
  • The trade is 0.9% of the 1,663,357 shares held after it.
  • 7 other insiders sold within 30 days.
  • 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO RAAB MICHAEL sold about $57.9K of ARDX on Aug 21, 2026; 7 other insiders sold within 30 days and 132 funds added in the latest 13F quarter.
RAAB MICHAEL
President & CEO
SELL
2026-08-25 SECtraded 2026-08-21
15,976
$61.6K
-21.7%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (1 buy, 61 sales), the last on Jul 15, 2026.
  • The trade is 1.0% of the 1,647,381 shares held after it.
  • 7 other insiders sold within 30 days.
  • 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO RAAB MICHAEL sold about $61.6K of ARDX on Aug 21, 2026; 7 other insiders sold within 30 days and 132 funds added in the latest 13F quarter.
RAAB MICHAEL
President & CEO
SELL
2026-08-25 SECtraded 2026-08-21
8,411
$32.4K
-21.7%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (1 buy, 61 sales), the last on Jul 15, 2026.
  • The trade is 0.5% of the 1,638,970 shares held after it.
  • 7 other insiders sold within 30 days.
  • 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO RAAB MICHAEL sold about $32.4K of ARDX on Aug 21, 2026; 7 other insiders sold within 30 days and 132 funds added in the latest 13F quarter.
RAAB MICHAEL
President & CEO
SELL
2026-08-25 SECtraded 2026-08-21
19,178
$74.0K
-21.7%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (1 buy, 61 sales), the last on Jul 15, 2026.
  • The trade is 1.2% of the 1,619,792 shares held after it.
  • 7 other insiders sold within 30 days.
  • 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO RAAB MICHAEL sold about $74.0K of ARDX on Aug 21, 2026; 7 other insiders sold within 30 days and 132 funds added in the latest 13F quarter.
Williams Laura A
Chief Patient Officer
SELL
2026-08-25 SECtraded 2026-08-21
3,486
$13.4K
-21.7%
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (1 buy, 32 sales), the last on Jun 18, 2026.
  • The trade is 0.9% of the 374,709 shares held after it.
  • 7 other insiders sold within 30 days.
  • 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Patient Officer Williams Laura A sold about $13.4K of ARDX on Aug 21, 2026; 7 other insiders sold within 30 days and 132 funds added in the latest 13F quarter.
346 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 341 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.2M over 180 days
-$486.2K over 90 days
below 71% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
132 funds bought in last quarter
more than 78% of Pharma & Biotech
Revenue
+22.1% year over year
more than 68% of Pharma & Biotech
Margin
-15.1% net margin
more than 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
13.1% of the float short (float per yahoo 2026-10-26) · 6.6 days to cover · settled 2026-09-30
more than 75% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ARDX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-40.7%12M
-41%-8%+25%+58%2025-102025-122026-022026-042026-062026-082026-10 2026-02-20 · MOTT DAVID M bought $1.9M2026-06-18 · Williams Laura A sold $490.6K2026-01-08 · Williams Laura A sold $349.0K2026-04-15 · RAAB MICHAEL sold $262.1K2026-05-15 · RAAB MICHAEL sold $261.7K2026-02-24 · RAAB MICHAEL sold $260.8K2025-11-21 · RAAB MICHAEL sold $259.8K2026-03-16 · RAAB MICHAEL sold $243.3K2026-02-20 · RAAB MICHAEL sold $237.2K2026-06-15 · RAAB MICHAEL sold $236.2K2026-07-15 · RAAB MICHAEL sold $210.9K2026-05-21 · RAAB MICHAEL sold $112.4K2026-05-21 · RAAB MICHAEL sold $93.6K2026-05-21 · RAAB MICHAEL sold $88.0K2026-08-21 · RAAB MICHAEL sold $74.0K2026-08-21 · Bishop John E sold $66.7K2026-08-21 · RAAB MICHAEL sold $61.6K2025-11-21 · Reilly Joseph James sold $61.4K2026-08-21 · RAAB MICHAEL sold $57.9K2026-02-20 · Foster Eric Duane sold $53.9K2026-08-21 · Brady James Parker sold $50.8K2026-02-20 · Kelliher Mike sold $49.5K2026-05-21 · RAAB MICHAEL sold $49.3K2026-02-20 · Williams Laura A sold $42.2K2025-11-21 · Williams Laura A sold $35.6K2025-11-21 · GRAMMER ELIZABETH A sold $33.2K2026-08-21 · RAAB MICHAEL sold $32.4K2025-11-21 · Foster Eric Duane sold $32.2K2026-02-20 · RAAB MICHAEL sold $31.8K2025-11-21 · Kelliher Mike sold $30.8K2026-02-20 · Reilly Joseph James sold $25.8K2026-05-21 · Foster Eric Duane sold $19.9K2026-05-21 · Kelliher Mike sold $18.2K2026-05-21 · Reilly Joseph James sold $16.8K2026-02-20 · Bishop John E sold $16.4K2026-05-21 · Kelliher Mike sold $15.5K2026-05-21 · Foster Eric Duane sold $15.2K2026-05-21 · Foster Eric Duane sold $15.1K2026-05-21 · Bishop John E sold $14.5K2026-05-21 · Williams Laura A sold $13.5K2026-08-21 · Williams Laura A sold $13.4K2026-02-20 · Brady James Parker sold $13.1K2026-08-21 · Bishop John E filed to sell $102.8K2026-08-21 · RAAB MICHAEL filed to sell $179.3K2026-08-21 · Williams Laura A filed to sell $42.3K2026-08-21 · Kelliher Mike filed to sell $42.3K2026-08-21 · Foster Eric Duane filed to sell $48.0K2026-08-21 · Reilly Joseph James filed to sell $18.9K2026-08-21 · Brady James Parker filed to sell $79.4K2026-08-21 · Hohenleitner Susan filed to sell $10.7K2026-06-18 · LAURA WILLIAMS filed to sell $478.3K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ARDX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
23,504,630 sh
$119.9M
Rubric Capital Management LP
16,202,700 sh
$82.6M
MILLENNIUM MANAGEMENT LLC
13,900,773 sh
$70.9M
STATE STREET CORP
13,356,128 sh
$68.1M
VANGUARD CAPITAL MANAGEMENT LLC
10,471,494 sh
$53.4M

Congress trades in ARDX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ARDX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Bishop John E
Filed 2026-08-21
$102.8K
RAAB MICHAEL
Filed 2026-08-21
$179.3K
Williams Laura A
Filed 2026-08-21
$42.3K
Kelliher Mike
Filed 2026-08-21
$42.3K
Foster Eric Duane
Filed 2026-08-21
$48.0K

ARDX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$5.5M position · as of 2026-07-31
2.0%
Virtus Biotech Etf
$1.2M position · as of 2026-07-31
1.2%
Nomura Small Cap Core Fund
$37.8M position · as of 2026-05-29
0.7%
Buffalo Early Stage Growth Fund
$447.0K position · as of 2026-06-30
0.6%
HUSSMAN STRATEGIC MARKET CYCLE FUND
$2.0M position · as of 2026-06-30
0.6%
Thrivent Small Cap Value ETF
$1.1M position · as of 2026-06-30
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
4
Phase 3
2 active
2
Phase 4
0 active
1
Multi-phase
0 active
What changed recently
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Pat
2026-09-23 · Active Not Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.2M sold by insiders over 180 days, 132 funds added last quarter, $523.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ARDX financials

Revenue growth
+22.1%
XBRL, annual
Net margin
-15.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$450.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-12.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$17.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.69x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Cash flow to debt
-0.07x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Return on equity
-38.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-10.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-8.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$902.2M
market value at close 2026-10-27 on 2026-07-30 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
FCF yield
-2.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$407.3M$333.6M$124.5M$52.2M
Operating income-$41.0M-$27.9M-$63.3M-$63.8M
Net income-$62.0M-$39.0M-$66.0M-$67.0M
EPS (diluted)-0.26-0.17-0.30-0.42
Operating cash flow-$42.5M-$44.8M-$89.7M-$70.0M
Cash$68.0M$64.9M$21.5M$96.1M
Long-term debt$202.8M$150.9M$49.8M$26.7M
SEC XBRL, fiscal years, as known on 2026-10-28

ARDX Stock Sonar score 6/7 axes

Find similar shapesCompare

ARDX ranks highest on institutional and government (86th percentile) and profitability (72nd), and lowest on insider conviction (14th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
72
Inputs
  • Return on equity-38.9% · 62 pct, sector of 545
  • Return on assets-10.8% · 74 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-8.6% · 80 pct, sector of 576
Financial health
41
Inputs
  • Debt to equity1.69x · 12 pct, sector of 352
  • Cash flow to debt-0.07x · 69 pct, sector of 371
Growth
68
Inputs
  • Revenue growth, YoY+22.1% · 68 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
14
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.2M · 27 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
86
Inputs
  • Funds adding, latest quarter132 · 78 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$5.5M · 94 pct, sector of 133
Risk and compliance
26
Inputs
  • Short interest, % of float+13.1% · 30 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+18.1% · 22 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ARDX filings, in plain words

Are Ardelyx insiders buying or selling ARDX?

In the 180 days to 2026-10-28, Ardelyx insiders were net sellers, a net $2.2M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of ARDX?

Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $523.7K of stock; the latest, by Bishop John E, was filed 2026-08-21.

Read the full summary

In the 180 days to 2026-10-28, Ardelyx insiders were net sellers of ARDX, a net $2.2M across purchases and sales reported on Form 4 by 8 sellers. None of the 44 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $523.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies